NCT04707248 - A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors | Biotech Hunter

Enrollment

179

Participants

Timeline

Start Date

December 22, 2020

Primary Completion Date

April 30, 2026

Study Completion Date

June 30, 2026

Conditions

Renal Cell CarcinomaOvarian Tumor

Interventions

DRUG

DS-6000a

Intravenous administration at doses starting at 1.6 mg/kg on Day 1 of Cycle 1

DRUG

DS-6000a

Intravenous administration at RDE on Day 1 of Cycle 1

Trial Locations (13)

Florida Cancer Lake Mary, Lake Mary

SCRI Oncology Partners, Nashville

Vanderbilt-Ingram Cancer Center, Nashville

Oklahoma University, Oklahoma City

Rocky Mountain Cancer Center, Denver

Arizona Oncology Associates, PC HOPE (A)A HOPE), Tucson

National Cancer Center Hospital, Chuo Ku

National Cancer Center Hospital East, Kashiwa-shi

National Hospital Organization Kyusyu Cancer Center, Fukuoka

The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Kōtoku

National Hospital Organization Shikoku Cancer Center, Matsuyama

Shizuoka Cancer Center, Nakatogari

Saitama Medical University International Medical Center, Saitama